Deuterium Metabolic MRI and [18F]-flourodesoxyglucose Positron Emission Tomography for Assessment of Treatment Response Following Radioembolization of Liver Metastasis; pilot study,

Deuterium Metabolic MRI and [18F]-flourodesoxyglucose Positron Emission Tomography for Assessment of Treatment Response Following Radioembolization of Liver Metastasis; pilot study, - DEPLETE

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON56433

Enrollment

Registered

2023-12-19

Start date

2024-02-01

Completion date

Unknown

Last updated

2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer livermetastasis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Adults (>=18 years) - Referred for SIRT and deemed eligible by the multidisciplinary tumor board - Size of at least one liver metastasis >= 1 cm on contrast enhanced CT / MRI (measurable according to RECIST 1.1) and 18FDG-avid metastatic liver disease (uptake > healthy liver uptake; measurable according to PERCIST) - Written informed consent

Exclusion criteria

Exclusion criteria: - Patients having FDG-negative disease (according to PERCIST) - Patients with diabetes mellitus - Patients having a general contra-indication for SIRT - Patients with contra-indications for 7T MR scanning - Patient unable to complete study scan (laying still for a long time) - Patient unable or incapable to follow study proceedings

Design outcomes

Primary

Measure	Time frame
To confirm safety and feasibility of 7T MRI scan prior to and after SIRT. Assess the prognostic value of baseline parameters and the magnitude of metabolic changes in 7T MRI scan. Compare technical performance of DMI to standard-of-care FDG-PET/CT.	—

Secondary

Measure	Time frame
n.a.	—

Countries

Netherlands

Outcome results